The strong efficacy of CD19-targeted CAR-T cell therapy in various hematologic malignancies is evident. This project initially focuses on the efficacy of an in-house developed, nanobody-based CAR-T cell therapy targeting CD70. Subsequently, the efficacy will be optimized via biparatopic CAR-T cell receptors as well as via HLA independent T-cell receptors to finally test this in PDX models.